Navigation Links
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Date:2/20/2008

lure, renal failure, pneumonia and sepsis. This integrated analysis does not include the Phase III, VELCADE plus DOXIL study.

For more information about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is http://www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achiev
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
4. Cellectar Expands Clinical Management Team
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
11. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Reportlinker.com announces that a ... catalogue: mHealth and Home Monitoring – ... Executive summary mHealth can ... better outcomes, decreased costs and improved sustainability of ... is still in an early stage, but on ...
(Date:7/30/2014)... brand ambassadors Fred Funk and Hal Sutton ... near Minneapolis, MN , which begins Friday at ... the official joint replacement products company of the PGA TOUR and ... through Sunday, August 3 rd , fans will be able to ... in the Pioneer Press Expo tent located near the clubhouse and ...
(Date:7/30/2014)... Calif. , July 30, 2014 Silicon ... released a study today that examines the ... and medical device companies.  According to the annual report ... the biggest potential returns since SVB started tracking the ... of the IPO.  Built on solid healthcare M&A activity ...
Breaking Medicine Technology:mHealth and Home Monitoring - 6th Edition 2mHealth and Home Monitoring - 6th Edition 3mHealth and Home Monitoring - 6th Edition 4mHealth and Home Monitoring - 6th Edition 5mHealth and Home Monitoring - 6th Edition 6mHealth and Home Monitoring - 6th Edition 7mHealth and Home Monitoring - 6th Edition 8mHealth and Home Monitoring - 6th Edition 9mHealth and Home Monitoring - 6th Edition 10mHealth and Home Monitoring - 6th Edition 11Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 2Report: Biopharma and Medical Device Companies Beat Historic Investment Returns 3
... findings presented today show that CONCERTA® (OROS® methylphenidate ... medication with data that demonstrate a significant treatment ... 12.5 hours in children with Attention Deficit Hyperactivity ... medical condition characterized by inattention, hyperactivity and impulsivity(1) ...
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... announced unaudited financial results for the three months ended ... September 30, 2009 , As of September 30, ... equivalents and an additional $50.9 million in investment securities, ...
Cached Medicine Technology:CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 2CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 3CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 4CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 5CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 6CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10
(Date:7/30/2014)... Alan Mozes HealthDay Reporter ... to help their preschooler shed excess pounds may want to ... whose parents joined them in a supervised behavioral modification program ... a traditional child-only program (an average difference of about four ... almost 15 pounds over two years, according to the study. ...
(Date:7/30/2014)... from the Church of Scientology of Denmark have joined ... distribution of Truth About Drugs education booklets. ... the famous Copenhagen walking street. Popular with tourists ... some quarter of a million people stroll down the ... activities are part of a coordinating effort by Scientologists ...
(Date:7/30/2014)... to fuel cancer as well as evolutionary changes in ... that occur randomly throughout the genome. , However, recent ... formation of multiple mutations that arise simultaneously and in ... mutations are frequently found in regions where chromosomal rearrangements ... Cell Reports , may one day lead to ...
(Date:7/30/2014)... Lexington, MA (PRWEB) July 30, 2014 ... provider of authentication, access management and secure communications ... Imprivata OneSign ® is the most widely ... using McKesson Paragon or Horizon electronic medical records ... (an increase of about 11 percent in the ...
(Date:7/30/2014)... IN (PRWEB) July 30, 2014 ... the opening of its new Carmel office on July ... staff will finally be moving to the state-of-the-art suite, ... cozy and innovative space will allow for one-on-one patient ... cosmetic surgery experience. , Dr. Hamilton’s new office-suite ...
Breaking Medicine News(10 mins):Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 2Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 3Health News:Make Kids' Weight Loss a Family Affair, Study Suggests 4Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2
... , , PASADENA, ... AIMM) today announced its licensee, BioMS Medical Corp., and ... meet the primary endpoint of delaying disease progression, as ... the two-year Phase III trial in patients with secondary ...
... EATONTOWN, N.J., July 30 Osteotech, Inc. (Nasdaq: ... for regenerative healing, announced today that its management team is scheduled ... Healthcare Conference at the Millennium Broadway Hotel in New York on ... A live, listen-only webcast of the presentation can be ...
... , , , , ... Corp. (Nasdaq: WBMD ) today announced financial results for the three ... to deliver strong results again this quarter. WebMD,s advertising revenue grew by 18% ... companies in the health and wellness markets," said Wayne Gattinella, President and CEO. ...
... , WASHINGTON, July 30 An estimated 700,100 residents ... a House health reform bill, according to state-specific analysis ... released this week by The Heritage Foundation . ... Lewin Group , a highly respected health care policy and ...
... NOVATO, Calif., July 30, BioMarin Pharmaceutical Inc. (Nasdaq: ... has issued patents covering stable tablet formulation and the approved once ... phenylketonuria (PKU). The patent for stable tablet formulation expires in ... in 2024. , , "We believe the issuance ...
... researchers say , THURSDAY, July 30 (HealthDay News) -- ... vaccine activates the immune system against the virus appear ... study finds. , According to Dutch researchers led by ... immune system goes on alert against the seasonal flu ...
Cached Medicine News:Health News:Clinical Trial by Licensee Does Not Meet Primary Endpoint 2Health News:WebMD Announces Second Quarter Financial Results 2Health News:WebMD Announces Second Quarter Financial Results 3Health News:WebMD Announces Second Quarter Financial Results 4Health News:WebMD Announces Second Quarter Financial Results 5Health News:WebMD Announces Second Quarter Financial Results 6Health News:WebMD Announces Second Quarter Financial Results 7Health News:WebMD Announces Second Quarter Financial Results 8Health News:WebMD Announces Second Quarter Financial Results 9Health News:WebMD Announces Second Quarter Financial Results 10Health News:WebMD Announces Second Quarter Financial Results 11Health News:WebMD Announces Second Quarter Financial Results 12Health News:WebMD Announces Second Quarter Financial Results 13Health News:WebMD Announces Second Quarter Financial Results 14Health News:WebMD Announces Second Quarter Financial Results 15Health News:WebMD Announces Second Quarter Financial Results 16Health News:WebMD Announces Second Quarter Financial Results 17Health News:WebMD Announces Second Quarter Financial Results 18Health News:WebMD Announces Second Quarter Financial Results 19Health News:Thousands of Nebraskans Could Lose Private Insurance, Study Shows 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 2Health News:Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan 3Health News:Flu Shot May Be Less Effective in Those With Lupus 2
Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Medicine Products: